Vicki L. Sato - 01 Jun 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role: Director
Signature: /s/ Tyler Nielsen, by power of attorney
Issuer symbol: DNLI
Transactions as of: 01 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 05 Jun 2023, 17:59:59 UTC
Previous filing: 24 May 2023
Next filing: 15 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNLI	Common Stock	Award	$0	+4,216	+3.2%	$0.000000	136,369	01 Jun 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNLI	Stock Option (right to buy)	Award	$0	+12,649		$0.000000	12,649	01 Jun 2023	Common Stock	12,649	$30.92	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2	Includes 4,216 unvested RSUs.
F3	The total reported in Column 5 has been adjusted to correct an overstatement of total holdings by 9,996 shares first reflected in a Form 4 filed on 06/02/2022.
F4	100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.